Jump to navigation Jump to search
Amlexanox Wiki Str.png
Clinical data
Trade namesAphthasol
Routes of
ATC code
Pharmacokinetic data
Elimination half-life3.5 hours
ExcretionRenal (17%)
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass298.293 g/mol
3D model (JSmol)
<templatestyles src="Nobold/styles.css"/>  (verify)

WikiDoc Resources for Amlexanox


Most recent articles on Amlexanox

Most cited articles on Amlexanox

Review articles on Amlexanox

Articles on Amlexanox in N Eng J Med, Lancet, BMJ


Powerpoint slides on Amlexanox

Images of Amlexanox

Photos of Amlexanox

Podcasts & MP3s on Amlexanox

Videos on Amlexanox

Evidence Based Medicine

Cochrane Collaboration on Amlexanox

Bandolier on Amlexanox

TRIP on Amlexanox

Clinical Trials

Ongoing Trials on Amlexanox at Clinical

Trial results on Amlexanox

Clinical Trials on Amlexanox at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Amlexanox

NICE Guidance on Amlexanox


FDA on Amlexanox

CDC on Amlexanox


Books on Amlexanox


Amlexanox in the news

Be alerted to news on Amlexanox

News trends on Amlexanox


Blogs on Amlexanox


Definitions of Amlexanox

Patient Resources / Community

Patient resources on Amlexanox

Discussion groups on Amlexanox

Patient Handouts on Amlexanox

Directions to Hospitals Treating Amlexanox

Risk calculators and risk factors for Amlexanox

Healthcare Provider Resources

Symptoms of Amlexanox

Causes & Risk Factors for Amlexanox

Diagnostic studies for Amlexanox

Treatment of Amlexanox

Continuing Medical Education (CME)

CME Programs on Amlexanox


Amlexanox en Espanol

Amlexanox en Francais


Amlexanox in the Marketplace

Patents on Amlexanox

Experimental / Informatics

List of terms related to Amlexanox

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Amlexanox (trade name Aphthasol) is an anti-inflammatory antiallergic immunomodulator used to treat recurrent aphthous ulcers (canker sores), and (in Japan) several inflammatory conditions. This drug has been discontinued in the U.S.[1]

Medical uses

Amlexanox is the active ingredient in a common topical treatment for recurrent aphthous ulcers of the mouth (canker sores),[2] reducing both healing time[3] and pain.[4] Amlexanox 5% paste is well-tolerated,[5] and is typically applied four times per day directly on the ulcers.[3] A 2011 review found it to be the most effective treatment of the eight treatments investigated for recurrent canker sores.[6] It is also used to treat ulcers associated with Behçet disease.[7]

In Japan, it is used to treat bronchial asthma, allergic rhinitis and conjunctivitis.[8]


The drug is contraindicated in those with known allergies to it.[3]

Adverse effects

Amlexanox may cause a slightly painful stinging or burning sensation, nausea or diarrhea.[3]

Mechanism of action

The drug is an anti-inflammatory,[8] antiallergic[9] immunomodulator.[10]

Its mechanism of action is not well-determined, but it might inhibit inflammation by inhibiting the release of histamine and leukotrienes.[8] It has been shown to selectively inhibt TBK1 and IKK-ε, producing reversible weight loss and improved insulin sensitivity, reduced inflammation and attenuated hepatic steatosis without affecting food intake in obese mice.[11]

Physical and chemical properties

The chemical itself is an odorless, white to yellowish-white powder.[8]

The 5% preparation for patient use is an adherent beige paste,[3][8] and it is also available in some countries as a tablet that adheres to the ulcer in the mouth.[4]


Amlexanox applied to an aphthous ulcer is largely absorbed through the gastrointestinal tract; an insignificant amount enters the bloodstream through the ulcer itself. After a single 100 mg dose, mean maximum serum concentration occurs 2.4 +/- 0.9 hours after application, with a half-life of elimination (through urine) of 3.5 +/- 1.1 hours. With multiple daily applications (four doses per day), steady state serum levels occur after one week, with no accumulation occurring after four weeks.[8]


The patent for its use as a treatment for aphthous ulcers was issued in November 1994 to inventors Kakubhai R. Vora, Atul Khandwala and Charles G. Smith, and assigned to Chemex Pharmaceuticals, Inc.[12]

Society and culture

Legal status

A prescription is required to obtain the medication.[13]


A 2011 review found a one week supply of amlexanox 5% paste to cost $30.[6]


A review found that, as of July 2011, robust studies investigating its effectiveness alongside other canker sore treatments were still needed.[14]

Because it is an inhibitor of the protein kinases TBK1 and IKK-ε,[11] which are implicated in the etiology of type II diabetes and obesity,[15] amlexanox may be a candidate for human clinical trials testing in relation to these diseases.[11]




  1. "Amlexanox (Aphthasol®)". Retrieved 20 November 2013.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  2. 2.0 2.1 Gonsalves WC, Chi AC, Neville BW (February 2007). "Common oral lesions: Part I. Superficial mucosal lesions". Am Fam Physician. 75 (4): 501–7. PMID 17323710.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  3. 3.0 3.1 3.2 3.3 3.4 3.5 "Amlexanox". MedlinePlus. U.S. National Library of Medicine. February 2009. Retrieved 12 February 2013.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  4. 4.0 4.1 4.2 Plewa MC (March 2012). "Pediatric Aphthous Ulcers Treatment & Management". Medscape Reference. Medscape. Retrieved 14 February 2013.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  5. 5.0 5.1 "Amlexanox". PubChem. U.S. National Library of Medicine. Retrieved 12 February 2013.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  6. 6.0 6.1 6.2 Bailey J, McCarthy C, Smith RF (October 2011). "Clinical inquiry. What is the most effective way to treat recurrent canker sores?". J Fam Pract. 60 (10): 621–32. PMID 21977491.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  7. 7.0 7.1 Yousefi M, Ferringer T, Lee S, Bang D (July 2012). "Dermatologic Aspects of Behcet Disease Treatment & Management". Medscape Reference. Medscape. Retrieved 14 February 2013.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  8. 8.0 8.1 8.2 8.3 8.4 8.5 8.6 Bell J (2005). "Amlexanox for the treatment of recurrent aphthous ulcers". Clin Drug Investig. 25 (9): 555–66. doi:10.2165/00044011-200525090-00001. PMID 17532700.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  9. 9.0 9.1 "Amlexanox". MeSH. U.S. National Library of Medicine. 2009. Retrieved 12 February 2013.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  10. 10.0 10.1 Elad S, Epstein JB, von Bültzingslöwen I, Drucker S, Tzach R, Yarom N (March 2011). "Topical immunomodulators for management of oral mucosal conditions, a systematic review; Part II: miscellaneous agents". Expert Opin Emerg Drugs. 16 (1): 183–202. doi:10.1517/14728214.2011.528390. PMID 21244328.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  11. 11.0 11.1 11.2 11.3 Reilly SM, Chiang SH, Decker SJ, Chang L, Uhm M, Larsen MJ, Rubin JR, Mowers J, White NM, Hochberg I, Downes M, Yu RT, Liddle C, Evans RM, Oh D, Li P, Olefsky JM, Saltiel AR (February 2013). "An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice". Nat. Med. 19 (3): 313–21. doi:10.1038/nm.3082. PMID 23396211.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  12. 12.0 12.1 US patent 5362737, Kakubhai R. Vora, Atul Khandwala, Charles G. Smith, "Methods of treating aphthous ulcers and other mucocutaneous disorders with amlexanox", assigned to Chemex Pharmaceuticals, Inc. 
  13. 13.0 13.1 Burgess JA, van der Ven PF, Martin M, Sherman J, Haley J (2008). "Review of over-the-counter treatments for aphthous ulceration and results from use of a dissolving oral patch containing glycyrrhiza complex herbal extract". J Contemp Dent Pract. 9 (3): 88–98. PMID 18335124.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  14. 14.0 14.1 Kuteyi T, Okwundu CI (2012). Kuteyi, Teslim, ed. "Topical treatments for HIV-related oral ulcers". Cochrane Database Syst Rev. 1: CD007975. doi:10.1002/14651858.CD007975.pub2. PMID 22258979.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  15. 15.0 15.1 Chiang SH, Bazuine M, Lumeng CN, Geletka LM, Mowers J, White NM, Ma JT, Zhou J, Qi N, Westcott D, Delproposto JB, Blackwell TS, Yull FE, Saltiel AR (September 2009). "The protein kinase IKKepsilon regulates energy balance in obese mice". Cell. 138 (5): 961–75. doi:10.1016/j.cell.2009.06.046. PMC 2756060. PMID 19737522.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  16. Template:Cite doi